Kite's Tecartus Shows 40% Four-Year Overall Survival Rate In Pivotal ZUMA-3 Study For Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Portfolio Pulse from Benzinga Newsdesk
Kite's Tecartus has demonstrated a 40% four-year overall survival rate in the pivotal ZUMA-3 study for relapsed/refractory B-cell acute lymphoblastic leukemia.
June 03, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kite, a subsidiary of Gilead Sciences (GILD), has reported that its Tecartus therapy shows a 40% four-year overall survival rate in the ZUMA-3 study for relapsed/refractory B-cell acute lymphoblastic leukemia.
The positive results from the ZUMA-3 study are likely to boost investor confidence in Gilead Sciences, as Kite is a subsidiary. This could lead to a short-term increase in GILD's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90